Geburtshilfe Frauenheilkd 2015; 75(06): 584-587
DOI: 10.1055/s-0035-1546151
Review
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

Bone-Targeted Therapy

Zielgerichtete Knochentherapie
J. Salmen
1   Universitätsfrauenklinik Düsseldorf, Heinrich-Heine Universität Düsseldorf, Düsseldorf
,
M. Banys-Paluchowski
2   Frauenklinik, Kath. Marienkrankenhaus Hamburg, Hamburg
,
T. Fehm
1   Universitätsfrauenklinik Düsseldorf, Heinrich-Heine Universität Düsseldorf, Düsseldorf
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 20. April 2015
revised 20. April 2015

accepted 07. Mai 2015

Publikationsdatum:
03. Juli 2015 (online)

   Lizenzen und Reprints

Abstract

Bisphosphonates and denosumab are well established components of the therapy for osteoporosis and osseous metastases. Their relevance in the adjuvant situation for breast cancer patients is being discussed in part controversially due to the heterogeneous nature of the available data. In particular, it appears that post-menopausal women benefit from an adjuvant therapy with bisphosphonates. In the present contribution we discuss the clinical relevance of osteoprotective therapy in the metastatic and adjuvant settings. Above all the current AGO guidelines on osteo-oncology and bone health have been taken into consideration for recommendations to implement the available data.

Zusammenfassung

Bisphosphonate und Denosumab sind fest etablierter Bestandteil der Therapie der Osteoporose und der ossären Metastasierung. Ihr Stellenwert in der adjuvanten Situation bei Mammakarzinompatientinnen wird aufgrund der heterogenen Datenlage teilweise kontrovers diskutiert. Insbesondere scheinen die postmenopausalen Patientinnen von der Bisphosphonattherapie in der Adjuvanz zu profitieren. In diesem Beitrag soll die klinische Relevanz der osteoprotektiven Therapien im metastasierten und adjuvanten Setting diskutiert werden. Bei den Empfehlungen für die Umsetzung der Daten wurden insbesondere die aktuellen AGO-Empfehlungen zur Osteoonkologie und zur Knochengesundheit berücksichtigt.

Key words

bisphosphonates - denosumab - breast cancer - adjuvant therapy - osteoporosis - bone metastases

Schlüsselwörter

Bisphosphonate - Denosumab - Mammakarzinom - adjuvante Therapie - Osteoporose - ossäre Metastasen

Supporting Information

 

  • References

  • 1 Domschke C, Schuetz F. Side effects of bone-targeted therapies in advanced breast cancer. Breast Care (Basel) 2014; 9: 332-336
    Google Scholar
  • 2 Fehm T, Felsenberg D, Krimmel M et al. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment. Breast 2009; 18: 213-217
    CrossrefGoogle Scholar
  • 3 Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2012; (2) CD003474
    Google Scholar
  • 4 Barrett-Lee P, Casbard A, Abraham J et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol 2014; 15: 114-122
    CrossrefGoogle Scholar
  • 5 Wang Z, Qiao D, Lu Y et al. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. Oncologist 2015; 20: 440-449
    CrossrefGoogle Scholar
  • 6 Lipton A, Fizazi K, Stopeck AT et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082-3092
    CrossrefGoogle Scholar
  • 7 Hortobagyi GN. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. J Clin Oncol 2014; 32: 5s (Suppl.; Abstr. LBA 9500)
    CrossrefGoogle Scholar
  • 8 Coleman R, de Boer R, Eidtmann H et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398-405
    CrossrefGoogle Scholar
  • 9 Gnant M, Mlineritsch B, Stoeger H et al. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015; 26: 313-320
    CrossrefGoogle Scholar
  • 10 Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21: 2188-2194
    CrossrefGoogle Scholar
  • 11 Coleman R, Gnant M, Paterson A et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomized trials. San Antonio Breast Cancer Symposium 2013; Abstr. S4-07.
    Google Scholar
  • 12 Gnant M, Mlineritsch B, Stoeger H et al. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 12: 631-641
    CrossrefGoogle Scholar
  • 13 Coleman R, Cameron D, Dodwell D et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 2014; 15: 997-1006
    CrossrefGoogle Scholar
  • 14 Paterson AH, Anderson SJ, Lembersky BC et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012; 13: 734-742
    CrossrefGoogle Scholar
  • 15 Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-363
    CrossrefGoogle Scholar
  • 16 Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802
    CrossrefGoogle Scholar
  • 17 Diel IJ, Jaschke A, Solomayer EF et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008; 19: 2007-2011
    CrossrefGoogle Scholar
  • 18 Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006; 8: R13
    CrossrefGoogle Scholar
  • 19 Saarto T, Vehmanen L, Virkkunen P et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004; 43: 650-656
    CrossrefGoogle Scholar
  • 20 von Minckwitz G, Möbus V, Schneeweiss A et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31: 3531-3539
    CrossrefGoogle Scholar
  • 21 AGO-Empfehlungen. Osteoonkologie und Knochengesundheit. Online: http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/maerz2015/de/2015D_21_Osteoonkologie_und_Knochengesundheit.pdf last access: 05.06.2015
    Google Scholar
  • 22 Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Online: http://www.awmf.org/uploads/tx_szleitlinien/032-045OL_k_S3__Brustkrebs_Mammakarzinom_Diagnostik_Therapie_Nachsorge_2012-07.pdf last access: 05.06.2015
    Google Scholar